The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a 20 percent gain in the first two months, a 24 percent drop from late February to mid-April, and a rebound of 16 percent off April lows by early June. This recent sell-off follows a 130 percent gain over the last three years and the debut of 100 biotech IPOs, leading some investors to ask if the recent sell-off is the start of a bubble bursting.
Indeed, the biotech sector has been hot for the last couple of years, but there is very little evidence to support that biotech has been forming a bubble ready to pop.
{iframe}http://www.biotech-now.org/business-and-investments/2014/06/debunking-the-biotech-bubble-talk?roi=echo4-26932824665-41071790-6a01603adb4685a08d1156f7ebb27e62&utm_source=newsletter&utm_medium=email&utm_campaign=0619#{/iframe}